Tag Archive for: AMR

Biocomposites launches SYNICEM™ spacers in the U.S.

Ready-to-use preformed antibiotic loaded spacers for hip, knee and shoulder revisions Choice of Charnley and Müller hip spacer designs, and left and right geometries for each knee Keele, UK, 21 October 2025 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and […]

Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.

BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN VG to treat diabetic foot osteomyelitis BLADE-OPU2 will evaluate the safety and efficacy of STIMULAN VG to treat stage IV pressure ulcers Keele, UK, 7 February 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management […]

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

COPENHAGEN, Denmark, Jan. 9, 2024 – The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this […]

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance

Novo Holdings today announced it has participated in the EUR 30 million Series A Financing of Bactolife. ATHOS led the round, with participation from the Bill & Melinda Gates Foundation, Novo Holdings and other existing investors. Bactolife is a Danish bioindustrial company developing proprietary Binding Proteins™, which strengthen the gut microbiome of humans and animals […]